Unlucky 13: Top Clinical Trial Failures of 2017
In Missing Their Primary Endpoints, These Drugs Sparked Layoffs, Losses, and a CEO Resignation
Cell Therapy Manufacturing: All Signs Point to Commercialization
As Milestones Are Reached, Best Practices Will Become Less Hazy
Seeking New Users for iSeq
The Changing Sequencing Landscape
Bioelectricity, New Peer Reviewed Journal Announced
An Outstanding and Influential Foundation for a Dynamic, Emerging Field
Lynn C. Klotz, Ph.D.
More GEN Content From This Contributor
- GEN Exclusives: What Is the Real Drug Development Cost for Very Small Biotech Companies?
- GEN Exclusives: Guiding Drug Development: A Pharmacoeconomic Look
- GEN Exclusives: The Promise of Combination Therapies
- GEN Exclusives: Big Pharma Issues and Strategy in a Single Visual
- GEN Exclusives: Why Big Pharma Needs Blockbusters
- GEN Exclusives: Why Is Everybody Picking on Sovaldi?